Glaukos iDose TR cuts eye pressure beyond cataract surgery alone, but will the advantage last?
Glaukos iDose TR shows an additional 3.6 mmHg pressure reduction with cataract surgery. Examine the Phase 4 data and adoption implications.
Medical Devices & Diagnostics
Pharma & Biotech
GlyphAgo boosted drug bioavailability 6.8-fold. Can Seaport solve agomelatine’s liver safety challenge?
Seaport's GlyphAgo improved agomelatine exposure in Phase 1. New Phase 2 trials will test efficacy, liver safety and anxiety outcomes.
Medical Devices & Diagnostics
Could a sensor 10 times shorter challenge Dexcom and Abbott? Ascensia is betting on Sava
Ascensia backs Sava's $36M glucose microsensor push, but clinical validation and CE marking remain critical before its planned European launch.
Medical Devices & Diagnostics
AIDS Healthcare Foundation brings an electric HIV clinic to Las Vegas, but can mobile testing improve access to treatment?
AIDS Healthcare Foundation brings free HIV testing and PrEP access to Las Vegas with an electric mobile clinic. See what its expansion means for care.
Medical Devices & Diagnostics
Why Quanta System’s ICE26 award comes at a crucial moment for its surgical laser business
Quanta System's ICE26 recognition brings its urology lasers, clinical evidence, US expansion and 2027 development plans into focus.
Pharma & Biotech
Verda Healthcare joins forces with AstranaCare in two states, but how much growth can the deal deliver?
Verda Healthcare partners with AstranaCare in Texas and Arizona ahead of Medicare enrollment. Discover the network and growth implications.
Medical Devices & Diagnostics
Genentech’s vamikibart sustains vision gains at 52 weeks, but mixed Phase III results complicate FDA review
Genentech's vamikibart sustained vision gains at 52 weeks, but mixed Phase III results leave questions ahead of a July 2027 FDA decision.
Pharma & Biotech
Can Merck’s remigromig compete with anti-VEGF treatments after BRUNELLO results?
Merck's remigromig met BRUNELLO's vision endpoint, but higher retinal complication rates complicate its potential in diabetic macular edema.
Medical Devices & Diagnostics
Haag-Streit’s Octopus 910 arrives in the US, but can it solve glaucoma testing’s biggest workflow problems?
Haag-Streit launches Octopus 910 in the US with automated glaucoma testing and HFA data import. Can it improve clinical workflows?
Pharma & Biotech
Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?
Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.